$SLDB
Solid Biosciences Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021027807 Filed on May 14, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $3.340M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.020M $5.250M
YoY Change 14.67% -25.32%
% of Gross Profit
Research & Development $14.21M $19.67M
YoY Change -27.78% -15.47%
% of Gross Profit
Depreciation & Amortization $734.0K $1.026M
YoY Change -28.46% 72.15%
% of Gross Profit
Operating Expenses $20.22M $26.86M
YoY Change -24.71% -11.36%
Operating Profit
YoY Change
Interest Expense -$14.00K $164.0K
YoY Change -108.54% -67.84%
% of Operating Profit
Other Income/Expense, Net -$14.00K $165.0K
YoY Change -108.48% -77.08%
Pretax Income -$16.90M -$26.69M
YoY Change -36.68% -9.77%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$16.90M -$26.69M
YoY Change -36.69% -9.76%
Net Earnings / Revenue -505.99%
Basic Earnings Per Share
Diluted Earnings Per Share -$189.3K -$555.3K
COMMON SHARES
Basic Shares Outstanding 46.07M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $268.5M $53.60M
YoY Change 400.93% -43.4%
Cash & Equivalents $268.5M $53.51M
Short-Term Investments $400.0K
Other Short-Term Assets $5.500M $4.300M
YoY Change 27.91% -38.57%
Inventory
Prepaid Expenses
Receivables $300.0K
Other Receivables $0.00
Total Short-Term Assets $274.3M $57.90M
YoY Change 373.74% -43.12%
LONG-TERM ASSETS
Property, Plant & Equipment $7.461M $15.50M
YoY Change -51.86% 29.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $500.0K
YoY Change -40.0% 139.23%
Total Long-Term Assets $10.98M $16.10M
YoY Change -31.78% -12.56%
TOTAL ASSETS
Total Short-Term Assets $274.3M $57.90M
Total Long-Term Assets $10.98M $16.10M
Total Assets $285.3M $74.00M
YoY Change 285.51% -38.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.194M $2.400M
YoY Change 33.08% -55.56%
Accrued Expenses $6.794M $10.30M
YoY Change -34.04% 18.39%
Deferred Revenue $10.66M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K $200.0K
YoY Change 0.0% 0.0%
Total Short-Term Liabilities $22.80M $12.90M
YoY Change 76.74% -11.47%
LONG-TERM LIABILITIES
Long-Term Debt $500.0K $700.0K
YoY Change -28.57% -12.5%
Other Long-Term Liabilities $9.000M $3.900M
YoY Change 130.77% -31.58%
Total Long-Term Liabilities $9.500M $4.600M
YoY Change 106.52% -29.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.80M $12.90M
Total Long-Term Liabilities $9.500M $4.600M
Total Liabilities $32.30M $17.50M
YoY Change 84.57% -17.06%
SHAREHOLDERS EQUITY
Retained Earnings -$421.5M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $253.0M $56.46M
YoY Change
Total Liabilities & Shareholders Equity $285.3M $74.00M
YoY Change 285.51% -38.45%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$16.90M -$26.69M
YoY Change -36.69% -9.76%
Depreciation, Depletion And Amortization $734.0K $1.026M
YoY Change -28.46% 72.15%
Cash From Operating Activities -$21.37M -$29.27M
YoY Change -27.01% 12.91%
INVESTING ACTIVITIES
Capital Expenditures $35.00K $681.0K
YoY Change -94.86% -65.13%
Acquisitions
YoY Change
Other Investing Activities $0.00 $7.100M
YoY Change -100.0% -258.13%
Cash From Investing Activities -$35.00K $6.418M
YoY Change -100.55% -199.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $135.1M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 135.2M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -21.37M -29.27M
Cash From Investing Activities -35.00K 6.418M
Cash From Financing Activities 135.2M 0.000
Net Change In Cash 113.8M -22.86M
YoY Change -597.69% -29.4%
FREE CASH FLOW
Cash From Operating Activities -$21.37M -$29.27M
Capital Expenditures $35.00K $681.0K
Free Cash Flow -$21.40M -$29.96M
YoY Change -28.56% 7.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4157000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-421469000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
253000000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
285279000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2419000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
525000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7461000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3196000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
274295000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-26694000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
165000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48059279
CY2020Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-26696000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
80048000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3104000
CY2021Q1 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
280000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-14000
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
164000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16900000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5518000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
327000
CY2021Q1 us-gaap Assets
Assets
285279000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3194000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6794000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1965000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10662000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10359000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7001000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
10359000
CY2021Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3335000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89267194
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6015000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14206000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5250000
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
1944000
CY2021Q1 sldb Pre Funded Warrants Outstanding
PreFundedWarrantsOutstanding
2158329
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
20221000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
26859000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-16900000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2907000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
253000000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1980000
CY2021Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
469000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16900000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
132086000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
8872000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
134878000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16866000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9437000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
55000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16900000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-26694000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
56456000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16900000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-26694000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
21000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2907000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3104000
CY2021Q1 us-gaap Depreciation
Depreciation
734000
CY2020Q1 us-gaap Depreciation
Depreciation
1026000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
769000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1205000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
280000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-90000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4309000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3916000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1175000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3055000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21366000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29274000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
681000
CY2020Q1 us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-7500000
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
401000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6418000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
135125000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
135154000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
113753000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22856000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155071000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76370000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
268824000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53514000
CY2021Q1 sldb Offering Costs In Accruals
OfferingCostsInAccruals
247000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-421469000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16900000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
268497000
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
327000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
268824000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155071000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, the recognition of research and development expenses and equity-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including clinical trials and employee-related amounts, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain it or treat its impact. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates. </p>
CY2021Q1 us-gaap Deposit Assets
DepositAssets
327000
CY2020Q4 us-gaap Deposit Assets
DepositAssets
327000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
327000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
327000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
268497000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154744000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
327000
CY2021Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
84462000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
84462000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
84462000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2020Q4 us-gaap Exchange Fees
ExchangeFees
200000
CY2020Q4 sldb Common Stock Shares Issued Warrant To Purchase
CommonStockSharesIssuedWarrantToPurchase
30000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.29
CY2020Q4 sldb Agreement Termination Period
AgreementTerminationPeriod
P60D
CY2020Q4 sldb Agreement Written Notice Period
AgreementWrittenNoticePeriod
P30D
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5422452
CY2021Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
84462000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q1 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
3467000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5518000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4157000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16898000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8713000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7461000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8153000
CY2021Q1 us-gaap Depreciation
Depreciation
734000
CY2020Q1 us-gaap Depreciation
Depreciation
1026000
CY2021Q1 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
2051000
CY2020Q4 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
2674000
CY2020Q4 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
1483000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6794000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8640000
CY2019Q3 sldb Gross Proceeds From Issuance Of Private Placement
GrossProceedsFromIssuanceOfPrivatePlacement
59977000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2397495
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2907000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3104000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16900000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26694000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89267194
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48059279
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4330997
CY2021Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.30
CY2020Q1 us-gaap Severance Costs1
SeveranceCosts1
1944000

Files In Submission

Name View Source Status
0001564590-21-027807-index-headers.html Edgar Link pending
0001564590-21-027807-index.html Edgar Link pending
0001564590-21-027807.txt Edgar Link pending
0001564590-21-027807-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sldb-10q_20210331.htm Edgar Link pending
sldb-10q_20210331_htm.xml Edgar Link completed
sldb-20210331.xsd Edgar Link pending
sldb-20210331_cal.xml Edgar Link unprocessable
sldb-20210331_def.xml Edgar Link unprocessable
sldb-20210331_lab.xml Edgar Link unprocessable
sldb-20210331_pre.xml Edgar Link unprocessable
sldb-ex101_41.htm Edgar Link pending
sldb-ex311_12.htm Edgar Link pending
sldb-ex312_7.htm Edgar Link pending
sldb-ex321_6.htm Edgar Link pending
sldb-ex322_10.htm Edgar Link pending